Evofem Biosciences (EVFM) investor relations material

Executive summary

• Commercial portfolio includes PHEXX (non-hormonal contraceptive gel) and SOLOSEC (single-dose antimicrobial for BV and trichomoniasis), with global rights to SOLOSEC acquired in July 2024.

• Shipped the 500,000th box of PHEXX, the only FDA-approved hormone-free, on-demand contraceptive vaginal gel.

• Expanded global reach with a distribution agreement for SOLOSEC in Sub-Saharan Africa and ongoing regulatory work in the UAE and Uganda.

• Added a new study site to an NIH-funded Phase 4 trial comparing SOLOSEC to metronidazole for trichomoniasis treatment.

• Company maintains a lean operating structure, focusing on top-line growth, cost alignment, and strategic partnerships for global expansion.

Financial highlights

• Q2 2026 net product sales: $2.6M, down from $4.8M in Q2 2025 (−45%), mainly due to lower PHEXX sales after a prior inventory build and temporary Medicaid exclusion.

• Net loss attributable to common stockholders for Q2 2026: $11.1M ($0.08 per share), compared to $1.8M ($0.01 per share) in Q2 2025, impacted by $2.2M debt extinguishment loss and $5.7M change in fair value of financial instruments.

• Six-month net loss: $16.6M (2026) vs. $0.8M (2025).

• Restricted cash and cash equivalents: $0.3M at June 30, 2026, compared to $0.6M at year-end 2025.

• Operating expenses decreased to $5.1M from $6.1M year-over-year, driven by reduced sales and marketing costs.

Outlook and guidance

• Management expects continued net losses and negative cash flows for the foreseeable future.

• Ongoing regulatory submissions for PHEXX and SOLOSEC in the UAE and Uganda, with expectations for expanded international market access.

• Plans to generate revenue from PHEXX and SOLOSEC, restructure payables, and seek additional funding through equity, debt, or partnerships.

• Substantial doubt exists about the ability to continue as a going concern without new funding.

• Continued focus on cost-effectiveness and clinical differentiation of SOLOSEC in trichomoniasis treatment.